PeptideDB

Drozitumab

CAS: 912628-39-8 F: W: 143.1 (kDa)

Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has poten
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma[1][2][3].
Invitro Drozitumab selectively eliminates cancer stem cells (CSCs), resulting in tumor growth inhibition and even regression of pancreatic tumors[3].Drozitumab induces apoptosis in mesenchymal TNBC cell lines but not in cell lines from other breast cancer subtypes[1].
Name Drozitumab
CAS 912628-39-8
Molar Mass 143.1 (kDa)
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Reference [1]. Dine JL, et al. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. Breast Cancer Res Treat. 2016 Jan;155(2):235-51. [2]. Kang Z, et al. Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response. Clin Cancer Res. 2011 May 15;17(10):3181-92. [3]. Eng JW, et al. Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5. J Immunother Cancer. 2016 Jun 21;4:33.